What is it about?
This is a linked comment for the published article on the Lancet Oncology (https://doi.org/10.1016/S1470-2045(24)00507-2). From the results of this important RCT, a standard treatment for patients with locally advanced HNSCC who are unfit for cisplatin remains out of reach.
Featured Image
Photo by National Cancer Institute on Unsplash
Why is it important?
Tretment option for the patients with locally advanced head and neck cancer who are unfit for cisplatin has been scarce and there remains still unmet needs.Although immune checkpoint inhibitors might have the potential to enhance the efficacy of radiotherapy, robust randomised trials should be designed based on solid evidence from previous studies, rather than the optimistic approach seen in recent trial designs.
Perspectives
Preservation of uninvolved lymph nodes might improve the tumour response to immune checkpoint inhibitors. Pursuing these possibilitiesin clinical trials might help optimise the potential of immune check point inhibitors with radiation therapy.
Naomi Kiyota
Kobe University Hospital
Read the Original
This page is a summary of: Patients with head and neck cancer unfit for cisplatin—what next?, The Lancet Oncology, December 2024, Elsevier,
DOI: 10.1016/s1470-2045(24)00597-7.
You can read the full text:
Contributors
The following have contributed to this page
